<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1654">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02116400</url>
  </required_header>
  <id_info>
    <org_study_id>AOI/2012/FC-02</org_study_id>
    <secondary_id>2012-A01673-40</secondary_id>
    <nct_id>NCT02116400</nct_id>
  </id_info>
  <brief_title>Neuropsychological Characterization of Patients With Bipolar Disorder and a History of Suicide Attempt</brief_title>
  <acronym>DECISIDAIRE</acronym>
  <official_title>Neuropsychological Characterization of Patients With Bipolar Disorder and a History of Suicide Attempt</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>France: Committee for the Protection of Personnes</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to evaluate decision-making using the Iowa Gambling Task
      (IGT) among patients with euthymic bipolar disorder according to their personal history of
      suicide attempt (&quot;suicidal&quot; vs. &quot;not suicidal &quot;).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The secondary objectives of this study are:

      A. Evaluate other aspects of cognitive functioning (using the Tower of London, the
      Probabilistic Reversal-learning task, the Rey Complex Figure, the Reading the Mind in the
      Eyes test) in euthymic patients with bipolar disorder, depending on the presence or absence
      of a history of suicide attempt; B. Explore performance on neuropsychological tests
      depending on the type of therapy administered  (lithium salts or valproate monotherapy or in
      combination with other mood stabilizers); C. Explore a possible relationship between
      circulating levels of lithium or sodium divalproex results and different neuropsychological
      tests; D. Establishment of a biobank for this population with leftover blood samples
      following  serum lithium or divalproex testing.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>Columbia-Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>Baseline (day 0)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>The Iowa Gambling Task</measure>
    <time_frame>Baseline (day 0)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Tower of London Test</measure>
    <time_frame>Baseline (day 0)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Probabilistic Reversal Learning Task</measure>
    <time_frame>Baseline (day 0)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Rey Osterreith Complex Figure Task</measure>
    <time_frame>Baseline (day 0)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Baron-Cohen Test</measure>
    <time_frame>Baseline (day 0)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration for divalproate (mg/l)</measure>
    <time_frame>Baseline (day 0)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration for lithium (mEq/l)</measure>
    <time_frame>Baseline (day 0)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Suicidal</arm_group_label>
    <description>Patients in this group have had suicidal behaviour according to the C-SSRS score.
Intervention: Interview Intervention: Neuropsychological testing Intervention: Serum concentration of lithium or sodium divalproate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Not suicidal</arm_group_label>
    <description>Patients in this group have not had suicidal behaviour according to the C-SSRS score.
Intervention: Interview Intervention: Neuropsychological testing Intervention: Serum concentration of lithium or sodium divalproate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Interview</intervention_name>
    <description>All patients are interviewed at the BEC.  Questionnaires and scores are administered. See endpoints.</description>
    <arm_group_label>Suicidal</arm_group_label>
    <arm_group_label>Not suicidal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neuropsychological testing</intervention_name>
    <description>Neuropsychological tests are administered (requires computer use).  See endpoints.</description>
    <arm_group_label>Suicidal</arm_group_label>
    <arm_group_label>Not suicidal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Serum concentration of lithium or sodium divalproate.</intervention_name>
    <description>Venous blood is drawn and tested for serum concentration of lithium or sodium divalproate.</description>
    <arm_group_label>Suicidal</arm_group_label>
    <arm_group_label>Not suicidal</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Leftover serum samples will be stored in the Nîmes University Hospital Biothèque.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients are recruited via the Bipolar Expert Centres (BEC) at the participating
        hospitals. Euthymic bipolar patients requiring a lithium or divalproex -based mood
        stabilizer will be included.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient was correctly informed about the study

          -  The patient must be insured or beneficiary of a health insurance plan

          -  The diagnosis of bipolar disorder is confirmed by the doctor referring the patient to
             the BEC and confirmed during the preliminary interview at the BEC

          -  The patient is euthymic on the day of inclusion. This is supported by a short
             psychiatric interview conducted at the BEC and the completion of the depression and
             mania scales (score &lt;= 7 on the HDRS questionnaire and score &lt;= 7 on the YMRS
             questionnaire).

          -  The patient is prescribed a mood stabilizer based on lithium or divalproex.

        Exclusion Criteria:

          -  The patient is under judicial protection, under tutorship or curatorship

          -  The patient formalizes his/her opposition to the studyd

          -  It is impossible to correctly inform the patient

          -  The patient has mental retardation

          -  The patient has practiced substance abuse or dependence within the 6 months prior to
             study inclusion (alcool, cannabis, opiates, psychostimulants)

          -  The patient does not meet euthymic criteria (score &lt;= 7 on the HDRS questionnaire and
             score &lt;= 7 on the YMRS questionnaire).

        Uninclusion Criteria:

          -  The patients withdraws consent during the study

          -  The patient does not understand directions necessary for the neurpsychological tasks

          -  The patient is not able to use a computer to complete the neuropsychological tasks
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabienne Cyprien, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU de Nîmes - Hôpital Universitaire Carémeau</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabienne Cyprien, MD</last_name>
    <phone>+33.0()4.66.68.38.74</phone>
    <email>fabienne.cyprien@chu-nimes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carey M Suehs, PhD</last_name>
    <phone>+33.(0)4.66.68.67.88</phone>
    <email>carey.suehs@chu-nimes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHRU de Montpellier - Hôpital Lapeyronie</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Philippe Courtet, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emilie Olie, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fanny Moliere, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Magali Seyller, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Nîmes - Hôpital Universitaire Carémeau</name>
      <address>
        <city>Nîmes Cedex 9</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Fabienne Cyprien, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mocrane Abbar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marilyn Wyart, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sabrina Mansard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 15, 2014</lastchanged_date>
  <firstreceived_date>April 15, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Suicidal ideation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Suicide</mesh_term>
    <mesh_term>Suicide, Attempted</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lithium</mesh_term>
    <mesh_term>Lithium Carbonate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
